All In Biotech

Drug Trial Radar · NCT00198718

Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates

Vitamin A Supplementation of Breast Feeding Mothers and Their Neonates at Delivery: Impact on Mother to Child Transmission of HIV During Lactation, HIV Infection Among Women During the Postpartum Year, and Infant Mortality.

Last checked: Nov 20, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 28,220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

28,220

Actual

Start

Nov 1997

Primary completion

May 2001

Study completion Dec 31, 2020

Sponsor

Lead sponsor
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre; University of Zimbabwe; Harare City Health Department, Harare, Zimbabwe; United States Agency for International Development (USAID); Bill and Melinda Gates Foundation; Rockefeller Foundation; BASF; SARA and Linkages Projects, Academy for Educational Development, Washington DC.; Université de Montréal
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The ZVITAMBO PROJECT is testing whether giving mothers and infants a single large dose of vitamin A during the immediate post partum period will reduce: 1. Infant Mortality Can oral administration of a single 50,000 IU dose of vitamin A to newborn infants, a single 400,000 IU dose of vitamin A given to their lactating mothers, or supplementation of both the mother and infant during the immediate post partum period reduce infant mortality by at least 30%? 2. Mother to Child HIV transmission during breast feeding Can oral administration of a single large dose of vitamin A given during the immediate post partum period to HIV seropositive lactating women and/or their babies reduce HIV transmission via breast feeding by at least 30%? 3. Sexually transmitted HIV infection of post partum women Can a single 400,000 IU dose of vitamin A given during the immediate post partum period to HIV seronegative women reduce their likelihood of becoming HIV infected during the post partum year by at least 25%? 4. Infant feeding in the context of HIV: An operational research study was initiated mid-way through the trial to determine how UNAIDS Guidelines on infant feeding in the context of HIV could be effectively implemented and to measure the impact of such a program on infant feeding practices and postnatal HIV transmission. Substudies: Random subsamples of maternal and infant blood were evaluated for anemia and iron status to determine the effect of vitamin A on hematopoiesis and serum and breast milk retinol (mothers) and modified relative dose response test (infants) to determine the effect of vitamin A on vitamin A status. A subsample of maternal and infant blood samples were evaluated for the presence of HLA-E, HLA-G, and TAP polymorphisms and their relation to prevalent HIV infection in mothers and risk of mother to child transmission.

Conditions

  • Vitamin A Deficiency
  • HIV

Interventions

  • Vitamin A (retinyl palmitate)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1. HIV infection rate among baseline HIV-negative babies born to HIV-positive mothers at 24 monthsTime frame: By 24 months of age
  2. 2. Infant mortality rate among all infants, infants born to HIV-negative mothers, and infants born to HIV-positive mothers at 6 monthsTime frame: by 12 months of age
  3. 3. HIV infection rates among baseline HIV-negative mothers at 24 monthsTime frame: by 24 months postpartum

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.